AI-ACCELERATED DRUG DISCOVERY

Decoding venom. Designing medicines.

We combine venom biology, high-throughput electrophysiology and AI to discover and engineer novel therapeutics.

Partner With Us
Venom discovery pipeline showing a venom specimen, peptide decoding, target prediction above a screening plate, an AI model, molecular synthesis and a final drug candidate
  1. VenomSource precision molecules
  2. DecodeResolve sequence and structure
  3. ScreenHigh-throughput Electrophysiology
  4. AILearn function and selectivity
  5. EngineerDesign and synthesize optimized candidates
  6. DrugAdvance therapeutic leads
The Venomics AI discovery pipeline progresses from venom through decoding, screening, AI analysis and synthesis to a drug candidate.
Supported by
Why Venomics AI

A discovery engine built on evolutionary intelligence.

20M+ unique bioactive peptides

Nature’s precision library

Millions of venom-derived peptides, evolved for potency and selectivity across biological targets.

100+ disease-relevant targets

Broad therapeutic reach

Searching nature’s molecular diversity across many disease-relevant targets

700M years of evolution

Evolution-optimised chemistry

Hundreds of millions of years of evolution. Built into every molecule.

भारत made in india

Built from India, for the world

Anchored in India’s extraordinary venom biodiversity and deep toxinology expertise.

The Precedent

This is not science fiction. Venom-derived drugs already exist.

Several important medicines were discovered from, or inspired by, venom.

FDA Approved 🐍

Captopril

Inspired by bradykinin-potentiating peptides in Brazilian pit viper (Bothrops jararaca) venom. The first ACE inhibitor to hit the market.

PEAK SALES: $1.6B / year
CLASS VALUE: $30B+

FDA Approved 1981

FDA Approved 🐚

Ziconotide (Prialt)

Derived from cone snail (Conus magus) toxin ω-conotoxin. A pioneering non-opioid analgesic for severe chronic pain.

POTENCY: 1,000× Morphine
TARGET MARKET: ~$70B (Pain)

FDA Approved 2004

FDA Approved 🦎

Exenatide (Byetta)

Based on exendin-4 from Gila monster (Heloderma suspectum) saliva. The foundational GLP-1 receptor agonist for type 2 diabetes.

PEAK SALES: $1.2B / year
CLASS VALUE: $20B+

FDA Approved 2005

Venomics AI is building a scalable discovery engine that transforms the intelligence encoded in venoms into new medicines.

Cone snail toxins pain therapeutics Gila monster saliva Exenatide / Byetta (diabetes) Brazilian pit viper Captopril (ACE inhibitor) Tarantula peptides chronic pain Sea anemone toxins autoimmune diseases Black mamba proteins analgesics Cone snail toxins pain therapeutics Gila monster saliva Exenatide / Byetta (diabetes) Brazilian pit viper Captopril (ACE inhibitor) Tarantula peptides chronic pain Sea anemone toxins autoimmune diseases Black mamba proteins analgesics
Therapeutic Focus

What Venomics AI is targeting

Five disease areas where venom biology offers transformative therapeutic potential.

Antimicrobial Resistance

Drug-resistant infections are outpacing the discovery of new antibiotics. Venom-derived peptides offer a rich source of molecules that can disrupt microbial membranes, modulate host defence, and reveal new antimicrobial mechanisms.

Venomics AI Focus

Discovering and engineering venom-derived antimicrobial candidates against resistant pathogens.

Diabetes & Weight Loss

Metabolic disease is one of the largest therapeutic markets in the world. Venom-associated molecules have already contributed to incretin biology and GLP-1-based therapeutics.

Venomics AI Focus

Identifying molecules that regulate appetite, glucose homeostasis, insulin secretion, energy balance, and metabolic signalling.

Senescence & Ageing Biology

Cellular senescence contributes to chronic inflammation, tissue dysfunction, fibrosis, cancer progression, and ageing-associated disease. Venom molecules can selectively modulate cell signalling, stress responses, survival pathways, and immune interactions.

Venomics AI Focus

Discovering molecules that help detect, modulate, or eliminate pathological senescent cells.

Ion Channels & Pain

Ion channels are central to pain, neurology, cardiac function, and cellular excitability. Venoms are among the richest natural sources of ion-channel modulators, especially peptide toxins with high potency and selectivity.

Venomics AI Focus

Targeting voltage-gated sodium, potassium, calcium, and other ion channels for pain, neurology, and related indications.

Cancer

Cancer cells depend on altered signalling, metabolism, membrane composition, immune evasion, and tumour-specific vulnerabilities. Venom-derived molecules can interact with receptors, ion channels, membranes, and tumour-associated pathways.

Venomics AI Focus

Developing venom-inspired molecules for tumour targeting, cytotoxicity, imaging, and precision oncology.

The Founders

Meet the minds behind the mission

A multidisciplinary team spanning toxinology, computational biology, and machine learning.

Director and Founder
Prof. Kartik Sunagar
Prof. Kartik Sunagar
Founder, Director
Professor, Centre for Ecological Sciences, Indian Institute of Science, Bengaluru

An evolutionary biologist at the Indian Institute of Science, Bengaluru, Prof. Sunagar has built one of India’s leading venom research programs. His work spans venom evolution, snakebite therapeutics, antibody discovery, small-molecule inhibitors, and the translational use of venom biology for medicine.

97Publications
6,222Citations
39h-index
71i10-index
36Journals
Director and Founder
Dr. Vinay Prabhu
Dr. Vinay Prabhu
Founder, CTO
PhD, Electrical & Computer Engineering Carnegie Mellon University MSEE · IIT Madras

Dr. Prabhu brings deep expertise in machine learning, large-scale AI systems, and computational biology. At Venomics AI, he leads the development of AI platforms that convert venom datasets into therapeutic insights and drug discovery programs.

42Publications
4,715Citations
13h-index
19i10-index
XJournals
Our Team
Scientific Foundation

Built on peer-reviewed science

Our platform builds on years of peer-reviewed research in venom biology, toxin pharmacology, and snakebite therapeutics.

Publications Archive
Field Notes

Dispatches from the Venom Detective

Stories from Prof. Kartik Sunagar on venom biology, snakebite, evolution, and the adventures that connect them.

All Field Notes
Updates

Latest Developments

Key milestones, funding announcements, and press features from the Venomics AI team.

Milestone January, 2026

Venomics AI Conceptualized

After 15 years of pursuing a shared passion for science and impact, Kartik and Vinay reunited in India to conceptualize Venomics AI and its mission.

A vision to decode nature’s most sophisticated molecules into life-changing medicines.

Company Milestone
Funding April, 2026

$3M Funding Raised

Venomics AI raised ~$3M in pre-seed funding to establish its integrated venom-to-therapeutics discovery platform.

Capital to build the discovery platform.

Funding Announcement
Grant August, 2026

Anthropic Grant

Our research partner, the Evolutionary Venomics Lab at IISc, has received a grant from Anthropic to advance its work at the intersection of venom biology, AI, and translational science.

Frontier AI brought to venom research.

Grant Announcement
All Updates
Get In Touch

Let's build the future of medicine together

Whether you're an investor, scientist, or patient advocate, we want to hear from you.

Direct contact info [at] venomics.ai

Partnerships, licensing, investor conversations, media, and scientific collaborations.

Location

No 33, 4th Floor, 1st Main, Ganganagar Gramatana, HMT, R T Nagar, Bengaluru 560032, Karnataka, India

Send us a message